These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 15613911)

  • 1. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
    Wu X; Patel D; Hasinoff BB
    J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
    Hasinoff BB; Yalowich JC; Ling Y; Buss JL
    Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
    Kik K; Szmigiero L
    Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
    Hasinoff BB; Schroeder PE; Patel D
    Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
    Hasinoff BB
    Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
    Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
    Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
    Xu X; Sutak R; Richardson DR
    Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
    Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
    Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
    Langer SW; Sehested M; Jensen PB
    Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.